Literature DB >> 8169844

Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture.

R Curi-Pedrosa1, M Daujat, L Pichard, J C Ourlin, P Clair, L Gervot, P Lesca, J Domergue, H Joyeux, G Fourtanier.   

Abstract

The ability of several gastric antiulcer drugs including lansoprazole, cimetidine and ranitidine to affect the expression of human liver microsomal cytochromes P450 comparatively to omeprazole, reported previously to be a CYP1A inducer, was evaluated in primary cultures of human hepatocytes. Poly (A)+ RNA and microsomes extracted from the cells were analyzed in Northern and Western blots with specific cDNA probes and antibodies, and assayed for form-specific monoxygenase activities. Lansoprazole induced both CYP1A1 and CYP1A2 as omeprazole and did not apparently bind to the aryl hydrocarbon receptor with high affinity. Omeprazole sulfone was not an inducer of CYP1A. Omeprazole, omeprazole sulfone and lansoprazole induced CYP3A in approximately 50% of tested cultures, whereas 100% of tested cultures responded to omeprazole and to rifampicin in terms of CYP1A and CYP3A induction, respectively. Finally, cimetidine and ranitidine were not inducers. We conclude that omeprazole and lansoprazole constitute a new class of mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture and that the induction of CYP3A in response to these molecules could be polymorphic in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169844

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 2.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

3.  Extended primary culture of human hepatocytes in a collagen gel sandwich system.

Authors:  Y Kono; S Yang; E A Roberts
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-06       Impact factor: 2.416

4.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

5.  Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

Authors:  T Andersson; J Holmberg; K Röhss; A Walan
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 6.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 7.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

9.  Immunochemical relationships of cytochrome P4503A-like proteins in teleost fish.

Authors:  M Celander; D R Buhler; L Förlin; A Goksøyr; C L Miranda; B R Woodin; J J Stegeman
Journal:  Fish Physiol Biochem       Date:  1996-08       Impact factor: 2.794

Review 10.  The search for endogenous activators of the aryl hydrocarbon receptor.

Authors:  Linh P Nguyen; Christopher A Bradfield
Journal:  Chem Res Toxicol       Date:  2007-12-13       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.